In particular, the latter concept that has
been proposed by the Amidon group showed some success as
the oral bioavailability of oseltamivir guanidine could be
increased to 23% (mice, fed state) and 48% (mice, fasted
state) with a carrier-mediated L-valinate prodrug.26